Business Wire

25 Years of Trust, Quality, and Health: SFI Health ™ celebrates Equazen ® milestone, the brand of food supplements developed to support cognitive needs

Share

SFI Health is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326323152/en/

Discover Equazen® comprehensive range: multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers. For more info visit www.equazen.com

The story of Equazen® began in 1999 in the UK with Prof. Horrobin’s groundbreaking research. Guided by his intuition, he researched certain pediatric cognitive function disorders stemming from a lack of essential fatty acids and their precursors. This insight led to the development of the first Equazen® product, originally known as Eye Q.

The product featured a unique combination of essential fatty acids, setting the foundation for Equazen®’s evolution while aligning with the company’s core philosophy: to harness the power of naturally sourced ingredients and adopt a pharma-quality approach to food supplements.

Since the publication of its first clinical evidence in 2005, Equazen® has been supported by over two decades of clinical trials. As a result, the brand is trusted globally by business partners, families and healthcare professionals to enhance learning capabilities, concentration, and overall cognitive well-being.

At the same time, Equazen® has evolved into multiple pharmaceutical formats and sizes to support the cognitive health of infants, children and teenagers.

One of the latest innovations is Equazen® Jelly, which combines the unique blend of essential fatty acids with a fruity flavor designed to appeal to picky eaters. Additionally, its patent-protected technology ensures the jelly is easy to swallow and promotes better natural absorption.

Matthew Brabazon, GM of SFI Heath EMEA, the regional entity of SFI Health, commented: It’s been an incredible journey watching Equazen® grow over the past 25 years to become a trusted brand globally. Looking ahead, we remain focused on the future and have exciting plans to continue bringing innovation to the market.”

Zbyszek Czop, Managing Director of Qpharma Sp. z o.o., distributor of Equazen® in Poland said: Earning the trust of doctors through the positive results of clinical studies on Equazen® is incredibly gratifying. Healthcare professionals now believe that Equazen® can make a meaningful difference for children, particularly those with behavioral disorders.”

Kirsten Jorsal, Founder of Novasel EU,distributor of Equazen® in Denmark added: Equazen® is a unique fatty acid supplement, distinguished by its balanced blend of polyunsaturated fatty acids, with a notably higher EPA content compared to DHA. Along with its strong clinical documentation, it stands apart from other fish oil supplements. Working with this product for so many years has been both rewarding, and receiving feedback from satisfied families has been truly fulfilling.”

A deep knowledge of consumers’ needs continues to guide the brand and inspires future innovations. The Equazen® range is proudly available in 30 countries across all continents, and the company is dedicated to expanding its reach, ensuring more consumers worldwide can benefit from its offerings.

About SFI Health

SFI Health is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.

Guided by the belief in the healing potential of natural products, SFI Health combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.

An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.

SFI Health is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.

For more information go to sfihealth.com or follow us SFI Health on LinkedIn.

About Equazen®

Equazen® is a science-based globally branded food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages.

Each product of the Equazen® range contains a balanced unique combination of essential fatty acids (Omega 3 and Omega 6), which has been clinically proven for more than 20 years to assist with learning capabilities, concentration and healthy brain development.

Equazen® is available in multiple pharmaceutical formats and sizes to support optimal cognitive functions from infants to teenagers.

Currently marketed in 30 countries globally, Equazen® is widely recommended by healthcare professionals and trusted by families for the last 25 years.

Equazen® aims to advance human health naturally, delivering expertly formulated products that empower individuals to reach their cognitive potential.

For more info visit www.equazen.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326323152/en/

Contacts

For more information
SFI Health™ EMEA Contact
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Geoquip Marine Secures €100million Bond to Accelerate Fleet Enhancements and Strategic Growth4.4.2025 09:00:00 CEST | Press Release

Geoquip Marine (Geoquip), a global leader in offshore geotechnical solutions and a Njord Partners portfolio company, is pleased to announce today it has successfully closed a €100million bond offering. This bond issuance significantly improves the Company’s cash balance, supports its continued growth, and is seen as a significant step in the Company’s ongoing maturation and development. The bond was placed after a successful roadshow with investors and will be used to advance key strategic initiatives. The immediate use of proceeds will be allocated between the repayment of existing debt and funding for two transformational projects: The Geoquip Silvretta: As announced in December, Geoquip Silvretta is currently in a shipyard in Norway undergoing work to create a state-of-the-art geotechnical services platform for the offshore energy sector. The vessel is on track to start operations in the first half of 2025. The Geoquip Elena: The Company is preparing to install a rig on Geoquip Elen

SES Announces Annual General Meeting Voting Results4.4.2025 08:50:00 CEST | Press Release

SES S.A. (“SES” or the “Company”) held the Company’s Annual General Meeting (“AGM”) at its headquarters in Betzdorf, Luxembourg, yesterday. The shareholders have voted all resolutions in accordance with the recommendations made by SES’s Board of Directors, notably the company’s 2024 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total amount includes the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) already paid to shareholders on 17 October 2024. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on 17 April 2025. Also as recommended by the Board of Directors, the shareholders approved the appointments of Mrs Ellen Lord and Mr John Shaw to the Board of Directors and the non-binding agenda item received from Atlas Infrastructure Partners regarding capital returns. “The outcome of the AGM is the result of SES’s ongoing commitment to productive shareholder engagement, ensur

ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy4.4.2025 08:00:00 CEST | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#

Western Union Offers Zero-Fee International Money Transfers to Myanmar4.4.2025 03:00:00 CEST | Press Release

In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the country. Effective immediately until midnight, 00:00 Myanmar Standard Time on 10 April 2025, individuals can send funds to Myanmar via WesternUnion.com or the Western Union mobile app, ensuring families can provide crucial support to their loved ones during this time of urgent need. Western Union remains committed to providing support during times of crisis, offering zero-fee transfers whenever possible to help communities in need. Money transfers sent to Myanmar will be: Available for payout into bank accounts. Available for payout into select mobile wallets Available for payouts incash at Agent locations2 “Our thoughts are with the people of Myanmar during this incredibly difficult time,” said Atish Shrestha, Western Union’s Regional Director for Indochina, South Korea and Taiwan, Western Un

Clean Tech Leader Aymium Defeats Stora Enso at European Patent Office Boards of Appeal4.4.2025 00:07:00 CEST | Press Release

Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for renewable battery applications. In its written opinion, the Boards of Appeal of the European Patent Office found Stora Enso's arguments brought before the board “not convincing” and agreed that a clarifying amendment to the claims did not extend the scope of protection of the patent. The ruling further affirms Aymium's position as the global leader in biocarbon materials for battery applications. Beyond the present ruling, Aymium owns a portfolio of more than 600 patents relating to biocarbon materials, compositions and manufacturing methods, including many specifically relevant to battery materials, and is the dominant global innovator regarding biocarbon materials. The ruling, combined with Aymium's massive patent portfolio, calls into question the ability of Stora Enso to produce bio-based ba

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye